Glucotrack, Inc. (GCTK) · Oct 19, 2026 · Share issuance
406,198 new warrants — 406,198 warrants at $7.50 exercise price; no new cash raised
Glucotrack’s new warrant deal lifts equity-issuance restrictions, giving its cash-hungry development program more financing flexibility at a dilution cost.
Glucotrack is still a development-stage medtech company building a fully implantable continuous blood-glucose monitor and advancing it toward U.S. clinical evaluation, rather than selling a commercial product today. The filing improves financing flexibility, not the product itself. Holders permanently waived the restriction that had limited new equity issuance and also waived their right to reset existing warrant exercise prices in a variable-rate transaction. 〔0〕 〔1〕 That removes a contractual obstacle if Glucotrack needs to raise more capital while it funds clinical and regulatory work.
The cost is a new layer of potential dilution. In exchange, Glucotrack must issue warrants for 406,198 shares at a $7.50 exercise price, with five-year lives; they cannot be exercised until stockholders approve the underlying share issuance. The 9.99% ownership cap limits immediate concentration for any holder, but the warrants still create a future claim on equity and the filing does not provide any new cash today.
This is a capital-structure maneuver, not a fresh financing or operating milestone. The market already understands that Glucotrack’s implantable-monitor program depends on additional funding; the new information is that the company has paid existing warrant holders for room to issue securities on more flexible terms. Bottom line: The waiver helps keep financing options open as Glucotrack advances its clinical program, but it does so by adding contingent dilution and does not extend the runway by itself.
Stockholder approval for Warrant Share issuance
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!